 |
|
Non-alcoholic fatty liver disease: Definition and subtypes
Seul Ki Han, Soon Koo Baik, Moon Young Kim
Clin Mol Hepatol. 2023;29(suppl):S5-S16. Published online 2022 Dec 28 DOI: https://doi.org/10.3350/cmh.2022.0424
|
|
Citations to this article as recorded by
 The interplay between chronic hepatitis B and diabetes mellitus: A narrative and concise review
Shang‐Chin Huang, Jia‐Horng Kao
The Kaohsiung Journal of Medical Sciences.2024; 40(1): 6. CrossRef LncRNA Gm28382 promotes lipogenesis by interacting with miR-326-3p to regulate ChREBP signaling pathway in NAFLD
Sen Yang, Yang Zhang, Yan Zhang, Lianhong Yin, Xu Han, Xuerong Zhao, Ning Wang, Lina Xu
International Immunopharmacology.2024; 127: 111444. CrossRef Role of Perturbated Hemostasis in MASLD and Its Correlation with Adipokines
Salvatore Pezzino, Tonia Luca, Mariacarla Castorina, Stefano Puleo, Saverio Latteri, Sergio Castorina
Life.2024; 14(1): 93. CrossRef From Nonalcoholic Fatty Liver Disease to Metabolic Dysfunction-Associated Steatotic Liver Disease: Out with the Old, in with the New
Iyiad Alabdul Razzak, Mazen Noureddin, Hirsh Trivedi
Journal of Clinical Medicine.2024; 13(3): 880. CrossRef Research Progress of MIF in Nonalcoholic Fatty Liver Disease
·阿不力提浦 阿依古扎丽
Advances in Clinical Medicine.2024; 14(02): 2483. CrossRef Hepatic Stellate Cell‐Targeting Micelle Nanomedicine for Early Diagnosis and Treatment of Liver Fibrosis
Lei Wang, Jieying Zhou, Jian Wang, Xiaotang Wang, Haijuan Dong, Lingzhi Zhao, Junchen Wu, Juanjuan Peng
Advanced Healthcare Materials.2024;[Epub] CrossRef Not Only Metabolic Complications of Childhood Obesity
Sebastian Ciężki, Emilia Odyjewska, Artur Bossowski, Barbara Głowińska-Olszewska
Nutrients.2024; 16(4): 539. CrossRef Effect of Statins for Primary Prevention of Cardiovascular Disease According to the Fatty Liver Index
Joonsang Yoo, Jimin Jeon, Minyoul Baik, Jinkwon Kim
Journal of Epidemiology and Global Health.2024; 14(3): 710. CrossRef Ferroptosis in Liver Disease: Natural Active Compounds and Therapeutic Implications
Zhili Wu, Yanru Zhu, Wenchao Liu, Balamuralikrishnan Balasubramanian, Xiao Xu, Junhu Yao, Xinjian Lei
Antioxidants.2024; 13(3): 352. CrossRef Lipidomic Analysis of Liver and Adipose Tissue in a High-Fat Diet-Induced Non-Alcoholic Fatty Liver Disease Mice Model Reveals Alterations in Lipid Metabolism by Weight Loss and Aerobic Exercise
Thomai Mouskeftara, Olga Deda, Grigorios Papadopoulos, Antonios Chatzigeorgiou, Helen Gika
Molecules.2024; 29(7): 1494. CrossRef Puerarin Induces Macrophage M2 Polarization to Exert Antinonalcoholic Steatohepatitis Pharmacological Activity via the Activation of Autophagy
Xiaoxue Fang, Xintian Lan, Ming Zhu, Min He, Mengmeng Sun, Yiming Cao, Difu Zhu, Dean Guo, Haoming Luo
Journal of Agricultural and Food Chemistry.2024; 72(13): 7187. CrossRef Metabolic-Associated Steatotic Liver Disease (MASLD): A New Term for a More Appropriate Therapy in Pediatrics?
Antonella Mosca, Andrea Pietrobattista, Giuseppe Maggiore
Pediatric Reports.2024; 16(2): 288. CrossRef Deciphering the molecular pathways of saroglitazar: A dual PPAR α/γ agonist for managing metabolic NAFLD
Devaraj Ezhilarasan
Metabolism.2024; 155: 155912. CrossRef Non-alcoholic fatty liver disease: new additional non-invasive diagnostic markers and risks of comorbid diseases
Kh.A. Moskva, O.P. Kikhtyak, M.L. Farmaha, Ya.L. Leshchuk, M.Yu. Horecha
INTERNATIONAL JOURNAL OF ENDOCRINOLOGY (Ukraine).2024; 20(2): 99. CrossRef SGLT2i impact on HCC incidence in patients with fatty liver disease and diabetes: a nation-wide cohort study in South Korea
Hyo Jung Cho, Eunyoung Lee, Soon Sun Kim, Jae Youn Cheong
Scientific Reports.2024;[Epub] CrossRef Roflumilast ameliorates GAN diet-induced non-alcoholic fatty liver disease by reducing hepatic steatosis and fibrosis in ob/ob mice
Bin Wang, Xiaochan Zhu, Siting Yu, Huan Xue, Lijiao Deng, Yushan Zhang, Yi Zhang, Yunfeng Liu
Biochemical and Biophysical Research Communications.2024; 722: 150170. CrossRef Small intestinal bacterial overgrowth in obese patients with biopsy-confirmed metabolic dysfunction-associated steatotic liver disease: a cross-sectional study
Nicolás Ortiz-López, Ana María Madrid, Larissa Aleman, Alejandra Zazueta, Gladys Smok, Lucía Valenzuela-Pérez, Jaime Poniachik, Caroll J. Beltrán
Frontiers in Medicine.2024;[Epub] CrossRef The effect of probiotic consumption on lipid profile, glycemic index, inflammatory markers, and liver function in NAFLD patients: A systematic review and meta-analysis of randomized controlled trials
Sadegh Mozaffari, Mahdeyeh Aliari, Solaleh Emamgholipour, Hossein Hosseini, Pedram Rezaei Amirkiasar, Mina Zare, Niki Katsiki, Ghodratollah Panahi, Amirhossein Sahebkar
Journal of Diabetes and its Complications.2024; 38(8): 108780. CrossRef SPRED2 Is a Novel Regulator of Autophagy in Hepatocellular Carcinoma Cells and Normal Hepatocytes
Tianyi Wang, Tong Gao, Masayoshi Fujisawa, Toshiaki Ohara, Masakiyo Sakaguchi, Teizo Yoshimura, Akihiro Matsukawa
International Journal of Molecular Sciences.2024; 25(11): 6269. CrossRef The independent and joint associations of vitamin B12 and methylmalonic acid on the risk of mortality in individuals with metabolic dysfunction-associated steatotic liver disease
Peng Wang, Jing Yu, Yaxuan Zhao, Rukiya Simayi, Dan Shi
European Journal of Nutrition.2024;[Epub] CrossRef Lycopene: A Potent Antioxidant with Multiple Health Benefits
Mercy Omoye Shafe, Nontobeko Myllet Gumede, Trevor Tapiwa Nyakudya, Eliton Chivandi, Toshikazu Suzuki
Journal of Nutrition and Metabolism.2024;[Epub] CrossRef Association between hemoglobin and non-alcoholic fatty liver disease (NAFLD) in United States adults: Results from NHANES 2017–2020
Kang Yao, Zheng Chen, Wei Zhou, Zhihua Liu, Wei Cui
Preventive Medicine Reports.2024; 44: 102798. CrossRef Effects of a Two-Year Lifestyle Intervention on Intrahepatic Fat Reduction and Renal Health: Mitigation of Inflammation and Oxidative Stress, a Randomized Trial
Maria Magdalena Quetglas-Llabrés, Margalida Monserrat-Mesquida, Cristina Bouzas, Silvia García, David Mateos, Miguel Casares, Cristina Gómez, Lucía Ugarriza, Josep A. Tur, Antoni Sureda
Antioxidants.2024; 13(7): 754. CrossRef The causal relationship between non-alcoholic fatty liver disease, hypertension, and cardiovascular diseases: implications for future research
Toshiki Maeda
Hypertension Research.2024; 47(9): 2580. CrossRef Role of Nonalcoholic Fatty Liver Disease in Periodontitis: A Bidirectional Relationship
Hardika S Vegda, Bhavin Patel, Gaurav A Girdhar, Mohd. Shabankhan H Pathan, Rahnuma Ahmad, Mainul Haque, Susmita Sinha, Santosh Kumar
Cureus.2024;[Epub] CrossRef Liver Cancer Risk Across Metabolic Dysfunction-Associated Steatotic Liver Disease and/or Alcohol: A Nationwide Study
Byungyoon Yun, Heejoo Park, Sang Hoon Ahn, Juyeon Oh, Beom Kyung Kim, Jin-Ha Yoon
American Journal of Gastroenterology.2024;[Epub] CrossRef Temporal relationship between hepatic steatosis and fasting blood glucose elevation: a longitudinal analysis from China and UK
Yujie Liu, Xian Liang, Yifan Hu, Ning Zhang, Xingren Zhu, Yuemei Feng, Zixiu Qin, Zihao Wang, Baima Kangzhuo, Xiong Xiao, Xing Zhao
BMC Public Health.2024;[Epub] CrossRef YinChen WuLing powder attenuates non-alcoholic steatohepatitis through the inhibition of the SHP2/PI3K/NLRP3 pathway
Xingxing Yuan, Liuxin Yang, Tinting Gao, Jiawei Gao, Bingyu Wang, Chengxiang Liu, Wei Yuan
Frontiers in Pharmacology.2024;[Epub] CrossRef The prevalence and effects of sarcopenia in patients with metabolic dysfunction-associated steatotic liver disease (MASLD): A systematic review and meta-analysis
Xiaoyan Li, Jie He, Qiuhua Sun
Clinical Nutrition.2024; 43(9): 2005. CrossRef Reversal of Fatty Liver With Regression of Acute Necrotizing Pancreatitis: A Rare Case
Sanjay M Khaladkar, Sayali Paidlewar, Purnachandra Lamghare, Ankita Pandey
Cureus.2024;[Epub] CrossRef Immune system dysregulation in the pathogenesis of non-alcoholic steatohepatitis: unveiling the critical role of T and B lymphocytes
Merve Cebi, Yusuf Yilmaz
Frontiers in Immunology.2024;[Epub] CrossRef Innovative treatments for obesity and NAFLD: A bibliometric study on antioxidants, herbs, phytochemicals, and natural compounds
Salvatore Pezzino, Maria Sofia, Chiara Mazzone, Giorgia Litrico, Luigi Piero Greco, Luisa Gallo, Gaetano La Greca, Saverio Latteri
Heliyon.2024; 10(16): e35498. CrossRef The pivotal role of dysregulated autophagy in the progression of non-alcoholic fatty liver disease
Qiaohui Shen, Ming Yang, Song Wang, Xingyu Chen, Sulan Chen, Rui Zhang, Zhuang Xiong, Yan Leng
Frontiers in Endocrinology.2024;[Epub] CrossRef MASLD-Related Hepatocarcinoma: Special Features and Challenges
Carmen Yagüe-Caballero, Diego Casas-Deza, Andrea Pascual-Oliver, Silvia Espina-Cadena, Jose M. Arbones-Mainar, Vanesa Bernal-Monterde
Journal of Clinical Medicine.2024; 13(16): 4657. CrossRef Metabolic Dysfunction-Associated Steatotic Liver Disease in Japan: Prevalence Trends and Clinical Background in the 10 Years before the Coronavirus Disease 2019 Pandemic
Akira Sato, Yumiko Oomori, Rika Nakano, Tomokazu Matsuura
Medicina.2024; 60(8): 1330. CrossRef Beneficial Effects of the Ketogenic Diet on Nonalcoholic Fatty Liver Disease (NAFLD/MAFLD)
Damian Dyńka, Łukasz Rodzeń, Mateusz Rodzeń, Dorota Łojko, Sebastian Kraszewski, Ali Ibrahim, Maria Hussey, Adam Deptuła, Żaneta Grzywacz, Alexandre Ternianov, David Unwin
Journal of Clinical Medicine.2024; 13(16): 4857. CrossRef Impact of non-alcoholic fatty liver disease on coronavirus disease 2019: A systematic review
Abdul Moeed, Muhammad Omar Larik, Muhammad Ahmed Ali Fahim, Hafsah Alim Ur Rahman, Lubna Najmi, Mah I Kan Changez, Muhammad Moiz Javed, Md Al Hasibuzzaman
World Journal of Hepatology.2024; 16(8): 1185. CrossRef Inter-visit and inter-reader reproducibility of multi-parametric diffusion-weighted MR imaging in longitudinally imaged patients with metabolic dysfunction-associated fatty liver disease and healthy volunteers.
Anton Volniansky, Thierry L. Lefebvre, Merve Kulbay, Boyan Fan, Emre Aslan, Kim-Nhien Vu, Emmanuel Montagnon, Bich Ngoc Nguyen, Giada Sebastiani, Jeanne-Marie Giard, Marie-Pierre Sylvestre, Guillaume Gilbert, Guy Cloutier, An Tang
Magnetic Resonance Imaging.2024; 113: 110223. CrossRef NFKBIE is a predictive factor of survival and is correlated with immune infiltration and antigen processing and presentation in hepatocellular carcinoma
Yang Zhang, Jinqi Tu, Jian Wang, Tiancheng Dai, Lin Zheng, Sinan Sun, Conyin Tu, Heng Li, Liting Qian
Oncology Letters.2024;[Epub] CrossRef New Onset of Acute and Chronic Hepatic Diseases Post-COVID-19 Infection: A Systematic Review
Ahamed Lebbe, Ali Aboulwafa, Nuran Bayraktar, Beshr Mushannen, Sama Ayoub, Shaunak Sarker, Marwan Nour Abdalla, Ibrahim Mohammed, Malik Mushannen, Lina Yagan, Dalia Zakaria
Biomedicines.2024; 12(9): 2065. CrossRef Emerging Therapies for Non-Alcoholic Steatohepatitis (NASH): A Comprehensive Review of Pharmacological and Non-Pharmacological Approaches
Shradha P Kakde, Maham Mushtaq, Maryyam Liaqat, Husnain Ali, Muhammad Muaz Mushtaq, Muhammad Asad Sarwer, Sami Ullah, Muhammad Wali Hassan, Asma Khalid, Syed Faqeer Hussain Bokhari
Cureus.2024;[Epub] CrossRef Metabolic Dysfunction-Associated Steatotic Liver Disease Is Associated with Increased Risk of Kidney Cancer: A Nationwide Study
Juyeon Oh, Beom Kyung Kim, Jin-Ha Yoon, Hyung Ho Lee, Heejoo Park, Jian Lee, Youngsun Park, Byungyoon Yun, Jinsoo Chung
Cancers.2024; 16(18): 3161. CrossRef Incidence of non-alcoholic fatty liver disease in antiretroviral therapy-naïve people with human immunodeficiency virus who start DTG/ABC/3TC compared to BIC/FTC/TAF at 48-week follow-up
Ana Luz Cano Díaz, Salma Triana González, Gloria Elizabeth Salinas Velázquez, José Antonio Mata Marín, Jesús Enrique Gaytán Martínez, Stefan Mauss
International Journal of STD & AIDS.2024;[Epub] CrossRef Rifaximin alleviates MCD diet-induced NASH in mice by restoring the gut microbiota and intestinal barrier
Yan Yun SHU, Li Lin HU, Jin YE, Ling YANG, Yu JIN
Life Sciences.2024; 357: 123095. CrossRef Salidroside may target PPARα to exert preventive and therapeutic activities on NASH
Xueru Chu, Shousheng Liu, Baozhen Qu, Yongning Xin, Linlin Lu
Frontiers in Pharmacology.2024;[Epub] CrossRef Metabolic dysfunction‐associated steatotic liver disease and MetALD increases the risk of liver cancer and gastrointestinal cancer: A nationwide cohort study
Yewan Park, Jooyi Jung, Seungbong Han, Gi‐Ae Kim
Alimentary Pharmacology & Therapeutics.2024;[Epub] CrossRef Lean vs. obese phenotypes of nonalcoholic fatty liver disease: similar or different?
Ho Soo Chun, Minjong Lee
Clinical and Molecular Hepatology.2023; 29(2): 377. CrossRef The Janus-Faced Role of Lipid Droplets in Aging: Insights from the Cellular Perspective
Nikolaus Bresgen, Melanie Kovacs, Angelika Lahnsteiner, Thomas Klaus Felder, Mark Rinnerthaler
Biomolecules.2023; 13(6): 912. CrossRef Protective effects of statins on the incidence of NAFLD–related decompensated cirrhosis in T2DM
Szu‐Yuan Wu, Wan‐Ming Chen, Ming‐Feng Chiang, Hung‐Chieh Lo, Ming‐Shun Wu, Ming‐Che Lee, Ruey‐Shyang Soong
Liver International.2023; 43(10): 2232. CrossRef Editorial: Will MRI‐PDFF become the new standard for steatosis assessment in NAFLD?
Angeliki Pappa, Tobias Wenzl
Alimentary Pharmacology & Therapeutics.2023; 58(3): 364. CrossRef Letter regarding “Non-alcoholic fatty liver disease: Definition and subtypes”
Seogsong Jeong, Yohwan Lim, Su Kyoung Lee, Hyun Wook Han
Clinical and Molecular Hepatology.2023; 29(3): 810. CrossRef Non-Alcoholic Fatty Liver Disease and Echocardiographic Parameters of Left Ventricular Diastolic Function: A Systematic Review and Meta-Analysis
Athina Goliopoulou, Panagiotis Theofilis, Evangelos Oikonomou, Artemis Anastasiou, Panteleimon Pantelidis, Maria Ioanna Gounaridi, Georgios E. Zakynthinos, Ourania Katsarou, Eva Kassi, Vaia Lambadiari, Dimitris Tousoulis, Manolis Vavuranakis, Gerasimos Si
International Journal of Molecular Sciences.2023; 24(18): 14292. CrossRef Critical appraisal of metabolic dysfunction-associated steatotic liver disease: Implication of Janus-faced modernity
Gi-Ae Kim, Joon Ho Moon, Won Kim
Clinical and Molecular Hepatology.2023; 29(4): 831. CrossRef Association between Impaired Ketogenesis and Metabolic-Associated Fatty Liver Disease
Jaehyun Bae, Byung-Wan Lee
Biomolecules.2023; 13(10): 1506. CrossRef The evolving role of lenvatinib at the new era of first-line hepatocellular carcinoma treatment
Landon L. Chan, Stephen L. Chan
Clinical and Molecular Hepatology.2023; 29(4): 909. CrossRef Comparison of the efficacy and safety of hypoglycemic treatments in patients with non-alcoholic fatty liver disease and type-2 diabetes: a systematic review and Bayesian network analysis
Nuojin Guo, Hekai Shi, Hao Zhang, Hua Wang
European Journal of Clinical Pharmacology.2023; 79(11): 1465. CrossRef Clinical Classification of Obesity and Implications for Metabolic Dysfunction-Associated Fatty Liver Disease and Treatment
Yuping Ding, Quanjun Deng, Mei Yang, Haiyan Niu, Zuoyu Wang, Shihai Xia
Diabetes, Metabolic Syndrome and Obesity.2023; Volume 16: 3303. CrossRef Health in All Policies: Working Across Sectors in Cooperative Extension to Promote Health for All
Michele Walsh, Deborah John, Nicole Peritore, Andrea Morris, Carolyn Bird, Marion Ceraso, Sarah Eichberger, Rachel Novotny, Laura Stephenson, Suzanne Stluka, Roberta Riportella
Journal of Human Sciences and Extension.2018;[Epub] CrossRef
|